117 related articles for article (PubMed ID: 38754340)
21. Validation of a continuous measure of cardiometabolic risk among adolescents.
Li K; Haynie DL; Gao X; Lipsky LM; Nansel T; Iannotti RJ; Vaca FE; Simons-Morton BG
J Pediatr Endocrinol Metab; 2021 Jun; 34(6):763-770. PubMed ID: 33823099
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs.
Abu-Farha M; Behbehani K; Elkum N
Cardiovasc Diabetol; 2014 Apr; 13():76. PubMed ID: 24716628
[TBL] [Abstract][Full Text] [Related]
23. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Atiomo WU; Fox R; Condon JE; Shaw S; Friend J; Prentice AG; Wilkin TJ
Clin Endocrinol (Oxf); 2000 Apr; 52(4):487-92. PubMed ID: 10762292
[TBL] [Abstract][Full Text] [Related]
24. Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study.
Raiko JR; Oikonen M; Wendelin-Saarenhovi M; Siitonen N; Kähönen M; Lehtimäki T; Viikari J; Jula A; Loo BM; Huupponen R; Saarikoski L; Juonala M; Raitakari OT
Atherosclerosis; 2012 Sep; 224(1):208-12. PubMed ID: 22840426
[TBL] [Abstract][Full Text] [Related]
25. A multifunctional diet improves cardiometabolic-related biomarkers independently of weight changes: an 8-week randomized controlled intervention in healthy overweight and obese subjects.
Tovar J; Johansson M; Björck I
Eur J Nutr; 2016 Oct; 55(7):2295-306. PubMed ID: 26370118
[TBL] [Abstract][Full Text] [Related]
26. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort.
Alessi MC; Nicaud V; Scroyen I; Lange C; Saut N; Fumeron F; Marre M; Lantieri O; Fontaine-Bisson B; Juhan-Vague I; Balkau B; Tregouet DA; Morange PE;
Thromb Haemost; 2011 Sep; 106(3):416-22. PubMed ID: 21800006
[TBL] [Abstract][Full Text] [Related]
27. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
28. Cardiometabolic risk among African American women: a pilot study.
Appel SJ; Oster RA; Floyd NA; Ovalle F
J Cardiovasc Nurs; 2009; 24(2):140-50. PubMed ID: 19242280
[TBL] [Abstract][Full Text] [Related]
29. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
30. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
31. Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits.
Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH
J Thromb Haemost; 2007 Feb; 5(2):313-20. PubMed ID: 17092303
[TBL] [Abstract][Full Text] [Related]
32. Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients.
Bilgili S; Celebiler AC; Dogan A; Karaca B
Endocr Regul; 2008 Jun; 42(2-3):63-8. PubMed ID: 18624608
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen Activator Inhibitor-1 in poorly controlled vs well controlled Type-2 Diabetes Mellitus patients: A case-control study in a district hospital in Ghana.
Nkansah C; Addai-Mensah O; Mensah K; Owusu M; Ephraim RKD; Adu P; Osei-Boakye F; Appiah SK; Serwaa D; Derigubah CA; Debrah AY
PLoS One; 2021; 16(4):e0250090. PubMed ID: 33857223
[TBL] [Abstract][Full Text] [Related]
34. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.
Sampson M; Kong C; Patel A; Unwin R; Jacobs HS
Clin Endocrinol (Oxf); 1996 Nov; 45(5):623-9. PubMed ID: 8977761
[TBL] [Abstract][Full Text] [Related]
35. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
[TBL] [Abstract][Full Text] [Related]
36. Relationship of metabolic syndrome and its components with -844 G/A and HindIII C/G PAI-1 gene polymorphisms in Mexican children.
De la Cruz-Mosso U; Muñoz-Valle JF; Salgado-Goytia L; García-Carreón A; Illades-Aguiar B; Castañeda-Saucedo E; Parra-Rojas I
BMC Pediatr; 2012 Mar; 12():41. PubMed ID: 22459021
[TBL] [Abstract][Full Text] [Related]
37. Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study.
Iida K; Tani S; Atsumi W; Yagi T; Kawauchi K; Matsumoto N; Hirayama A
Coron Artery Dis; 2017 Nov; 28(7):577-587. PubMed ID: 28692480
[TBL] [Abstract][Full Text] [Related]
38. Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioural variables.
Cigolini M; Targher G; Seidell JC; Tonoli M; Schiavon R; Agostino G; De Sandre G
J Hypertens; 1995 Jun; 13(6):659-66. PubMed ID: 7594424
[TBL] [Abstract][Full Text] [Related]
39. Acute ingestion of long-chain (n-3) polyunsaturated fatty acids decreases fibrinolysis in men with metabolic syndrome.
Montegaard C; Tulk HM; Lauritzen L; Tholstrup T; Robinson LE
J Nutr; 2010 Jan; 140(1):38-43. PubMed ID: 19889809
[TBL] [Abstract][Full Text] [Related]
40. Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome.
de Sá MC; Simão ANC; de Medeiros FA; Iriyoda TMV; Costa NT; Alfieri DF; Flauzino T; Sekiguchi BA; Lozovoy MAB; Reiche EMV; Maes M; Dichi I
Clin Exp Med; 2018 Nov; 18(4):495-504. PubMed ID: 30008151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
